ChemoCentryx, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2012-11-15: Form 8-K; Period of report 2012-11-13; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2012-08-13: Form 8-K; Period of report 2012-08-10; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2012-07-27: Form 8-K; Period of report 2012-07-24; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2012-06-27: Form 8-K; Period of report 2012-06-22; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2012-11-15 | 8-K | 2012-11-13 | 2.02 Results of Operations and Financial Condition | 2.02 On November 13, 2012, ChemoCentryx, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2012. | d441241d8k.htm |
| 2012-08-13 | 8-K | 2012-08-10 | 2.02 Results of Operations and Financial Condition | 2.02 On August 10, 2012, ChemoCentryx, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2012. | d397019d8k.htm |
| 2012-07-27 | 8-K | 2012-07-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 24, 2012, the Compensation Committee of the Board of Directors (the “Committee”) of ChemoCentryx, Inc. (the “Company”) approved and awarded stock options to the executive officers listed below (the “Named Executive Officers”) under the Company’s 2012 Equity Incentive Award Plan. | d385847d8k.htm |
| 2012-06-27 | 8-K | 2012-06-22 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 ChemoCentryx, Inc. (the “Company”) held its annual meeting of stockholders on June 22, 2012. | d372720d8k.htm |
| 2012-06-08 | 8-K | 2012-06-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 Effective as of June 5, 2012, upon the recommendation of the Nominating and Corporate Governance Committee, and pursuant to the bylaws of ChemoCentryx, Inc. (the “Company”), the Board of Directors (the “Board”) of the Company appointed James L. Tyree, age 59, to the Board. 7.01 On June 7, 2012, the Company issued a press release announcing Mr. Tyree’s appointment. | d366173d8k.htm |
| 2012-05-11 | 8-K | 2012-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2012, ChemoCentryx, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2012. | d351123d8k.htm |
| 2012-05-01 | 8-K | 2012-04-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 Effective as of April 25, 2012, upon the recommendation of the Nominating and Corporate Governance Committee, and pursuant to the bylaws of ChemoCentryx, Inc. (the “Company”), the Board of Directors (the “Board”) of the Company appointed Joseph M. Feczko, M.D. to fill a vacancy on the Board. 7.01 On April 30, 2012, the Company issued a press release announcing Dr. Feczko’s appointment. | d343178d8k.htm |
| 2012-04-02 | 8-K | 2012-03-30 | 2.02 Results of Operations and Financial Condition | 2.02 On March 30, 2012, ChemoCentryx, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2011. | d328290d8k.htm |
| 2012-03-02 | 8-K | 2012-02-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 27, 2012, the Compensation Committee of the Board of Directors (the “Committee”) of ChemoCentryx, Inc. (the “Company”) established the base salaries to be paid to the executive officers listed below (the “Named Executive Officers”), effective January 1, 2012. | d308491d8k.htm |